Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.12M$1.12Mderived+40.9% vs Q4 2019 Net Income-$3.54M-$3.54MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$2,929,000N/M Operating Cash Flowderived-$3,867,000N/M Free Cash Flowderived-$4,674,000N/M Margins · derivedOperating margin-261.5%+248.3 pt vs Q4 2019
Net margin-315.9%+250.5 pt vs Q4 2019
ended Jun 30, 2020 · filed Oct 13, 2020 · 105 d after period end